rocuronium hospira 10 mg/ml injektions-/infusionsvätska, lösning
pfizer ab - rokuroniumbromid - injektions-/infusionsvätska, lösning - 10 mg/ml - rokuroniumbromid 10 mg aktiv substans - rokuroniumbromid
sotalol 2care4 160 mg tablett
2care4 aps - sotalolhydroklorid - tablett - 160 mg - sotalolhydroklorid 160 mg aktiv substans - sotalol
sotalol viatris 40 mg tablett
viatris limited - sotalolhydroklorid - tablett - 40 mg - sotalolhydroklorid 40 mg aktiv substans - sotalol
sotacor 80 mg tablett
cheplapharm arzneimittel gmbh - sotalolhydroklorid - tablett - 80 mg - sotalolhydroklorid 80 mg aktiv substans; laktosmonohydrat hjälpämne - sotalol
sotalol viatris 80 mg tablett
viatris limited - sotalolhydroklorid - tablett - 80 mg - sotalolhydroklorid 80 mg aktiv substans - sotalol
sotalol 2care4 80 mg tablett
2care4 aps - sotalolhydroklorid - tablett - 80 mg - sotalolhydroklorid 80 mg aktiv substans - sotalol
aggrastat 250 mikrogram/ml koncentrat till infusionsvätska, lösning
correvio - tirofibanhydrokloridmonohydrat - koncentrat till infusionsvätska, lösning - 250 mikrogram/ml - tirofibanhydrokloridmonohydrat 281 mikrog aktiv substans - tirofiban
aggrastat 50 mikrogram/ml infusionsvätska, lösning
correvio - tirofibanhydrokloridmonohydrat - infusionsvätska, lösning - 50 mikrogram/ml - tirofibanhydrokloridmonohydrat 56 mikrog aktiv substans - tirofiban
sotalol ebb 80 mg tablett
ebb medical ab - sotalolhydroklorid - tablett - 80 mg - sotalolhydroklorid 80 mg aktiv substans
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiska medel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.